1. Home
  2. JELD vs TNXP Comparison

JELD vs TNXP Comparison

Compare JELD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$2.76

Market Cap

243.5M

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$17.15

Market Cap

231.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
TNXP
Founded
1960
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.5M
231.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
JELD
TNXP
Price
$2.76
$17.15
Analyst Decision
Hold
Buy
Analyst Count
7
1
Target Price
$4.23
$70.00
AVG Volume (30 Days)
1.6M
638.0K
Earning Date
11-03-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,304,951,000.00
$10,299,000.00
Revenue This Year
N/A
$14.79
Revenue Next Year
N/A
$933.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$6.76
52 Week High
$10.09
$72.00

Technical Indicators

Market Signals
Indicator
JELD
TNXP
Relative Strength Index (RSI) 47.83 43.38
Support Level $2.66 $17.71
Resistance Level $3.00 $19.35
Average True Range (ATR) 0.15 1.34
MACD 0.08 0.04
Stochastic Oscillator 48.99 37.55

Price Performance

Historical Comparison
JELD
TNXP

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: